C4 Therapeutics - Company Profile - Tracxn

C4 Therapeutics - Developer of small molecule drugs for treating cancer. Public Company. Raised a total funding of $223M over 4 rounds from 27 investors. Founded by Marc A Cohen in the …

CouponFollow Extension

$223
OFF

C4 Therapeutics - Company Profile - Tracxn

6 days from now

C4 Therapeutics - Developer of small molecule drugs for treating cancer. Public Company. Raised a total funding of $223M over 4 rounds from 27 investors. Founded by Marc A Cohen in the …

tracxn.com

$243
OFF

C4 Therapeutics Stock Price, Funding, Valuation, Revenue

6 days from now

Funding, Valuation & Revenue. 6 Fundings. C4 Therapeutics has raised $243M over 6 rounds.. C4 Therapeutics's latest funding round was a Corporate Minority - P2P for $25M on May 29, …

cbinsights.com

$25
OFF

C4 Therapeutics Announces Closing Of $25 Million Equity

6 days from now

Jan 4, 2024 · C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to …

globenewswire.com

$25
OFF

C4 Therapeutics, Inc. (CCCC) - Stock Analysis

6 days from now

4 days ago · C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals. WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- C4 …

stockanalysis.com

30%
OFF

C4 Lays Off 30% Of Staff In Aftermath Of Halting Cancer Drug

6 days from now

Jan 10, 2024 · C4 announced on Nov. 1 that it was halting work on an oral BRD9 degrader called CFT8634 in synovial sarcoma and SMARCB-1 null tumors after the high levels of BRD9 …

fiercebiotech.com

$223
OFF

Avenzo Therapeutics - Raised $223M Funding From 10 Investors

6 days from now

Oct 22, 2024 · Avenzo Therapeutics has raised a total funding of $223M over 1 round from 10 investors. Investors include Sofinnova Investments, New Enterprise Associates and 8 others. …

tracxn.com

$223
OFF

Arvelle Therapeutics - Raised $223M Funding From 11 Investors

6 days from now

Nov 13, 2024 · Arvelle Therapeutics has raised a total funding of $223M over 2 rounds from 11 investors. Investors include EQT, Life Sciences Partners and 9 others. Their latest funding …

tracxn.com

FAQs about C4 Therapeutics - Company Profile - Tracxn Coupon?

How many investors does C4 Therapeutics have?

C4 Therapeutics has 24 investors including Betta Pharmaceuticals and Taiwania Capital Management Corporation. How much funding has C4 Therapeutics raised to date? C4 Therapeutics has raised When was the last funding round for C4 Therapeutics? C4 Therapeutics closed its last funding round on May 30, 2023 from a Post-IPO Equity round. ...

When did C4 Therapeutics close?

C4 Therapeutics closed its last funding round on May 30, 2023 from a Post-IPO Equity round. Who are C4 Therapeutics's competitors? Alternatives and possible competitors to C4 Therapeutics may include Aligos Therapeutics, HAYA Therapeutics, and Inhibikase Therapeutics. ...

Where is C4 Therapeutics located?

C4 Therapeutics is located in Cambridge, Massachusetts, United States. Who invested in C4 Therapeutics? C4 Therapeutics has 24 investors including Betta Pharmaceuticals and Taiwania Capital Management Corporation. How much funding has C4 Therapeutics raised to date? C4 Therapeutics has raised When was the last funding round for C4 Therapeutics? ...

Who is C4 Therapeutics (c4t)?

WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in fireside chats at two September investor ...

What does C4 Therapeutics do in 2024?

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced 2024 priorities to execute against its strategic plan to leverage the benefits of targeted protein degradation across drug discovery and clinical development to create and deliver breakthrough therapies... ...

Who is the new CEO of C4 Therapeutics?

WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen ...